Effects of sulbutiamine on diabetic polyneuropathy: an open randomised controlled study in type 2 diabetics.

about

Effects of sulbutiamine on diabetic polyneuropathy: an open randomised controlled study in type 2 diabetics.

Item

http://www.wikidata.org/entity/Q42106052

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Effects of sulbutiamine on dia ...... led study in type 2 diabetics.

@en

Effects of sulbutiamine on dia ...... led study in type 2 diabetics.

@nl

type

Item

label

Effects of sulbutiamine on dia ...... led study in type 2 diabetics.

@en

Effects of sulbutiamine on dia ...... led study in type 2 diabetics.

@nl

prefLabel

Effects of sulbutiamine on dia ...... led study in type 2 diabetics.

@en

Effects of sulbutiamine on dia ...... led study in type 2 diabetics.

@nl

P1476

Effects of sulbutiamine on dia ...... lled study in type 2 diabetics

@en

P2093

A Ridzuan

http://www.w3.org/2001/XMLSchema#string

K K Kiew

http://www.w3.org/2001/XMLSchema#string

M Mafauzy

http://www.w3.org/2001/XMLSchema#string

W B Wan Mohamad

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues

Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat

A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.

Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation.

Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235.

Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy.

The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.

Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. Ponalrestat Study Group.

P304

21-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22969314

http://www.w3.org/2001/XMLSchema#string

P932

3436103

http://www.w3.org/2001/XMLSchema#string